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I. ABSTRACT 
 
Cocaine and other dopamine transporter (DAT) inhibitors block synaptic 
dopamine uptake by binding to the DAT.  Cocaine, a powerful psychostimulant, 
potentiates the dopamine mediated signal transduction in the reward areas of the 
brain resulting in physical dependence on the drug.  Amphetamines are 
psychotomimetics that act as substrates at the DAT and potentiate dopaminergic 
neurotransmission leading to addiction.  It was previously reported that a 
conservative glutamate-for-aspartate substitution in transmembrane 1 domain of 
the rat DAT protein (D79E) significantly decreased the binding affinities of 
several classical DAT inhibitors, but had little or no effect on the dopamine 
uptake inhibition potencies (DUIPs) of these blockers.  This finding implied that 
different DAT sites/conformations/populations may be responsible for dopamine 
uptake and for high affinity binding of inhibitors.  In the present study, the DUIPs 
of cocaine and other DAT ligands at wildtype DAT CHO cells fluctuated as a 
function of cell age, while their binding affinities remained static.  Curiously, 
neither the DUIP nor the binding affinity of amphetamine fluctuated with cell age.  
The DUIP fluctuations of cocaine also extended to the N2A neuronal cells, 
demonstrating its physiological relevance.  The loss of correlation between DUIP 
and binding affinity at DAT might be a unique property of DAT blockers that is not 
exhibited by DAT substrates.  A plausible explanation for the DUIP fluctuations 
with cell age is the existence of two different DAT populations on the cell surface, 
the relative distribution of which changes with cell age under the influence of 
intracellular events such as DAT-protein interactions or alterations in the 
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phosphorylation state.  Several proteins interact with the N- and C-terminal 
regions of the DAT.  Studies employing GFP fusion polypeptides of the DAT N- 
or C-terminal fragments, which would act as decoys by intercepting DAT 
modulators, showed that the DAT N- or C-terminal interactions with intracellular 
proteins do not appear to be responsible for the DUIP shift.  The role of 
phosphorylation state changes of DAT in DUIP fluctuations was also 
investigated.  Studies employing a mutant DAT lacking the first 20 N-terminal 
amino acids demonstrated that N-terminal phosphorylation of DAT, specifically 
involving the first five serines is not associated with the DUIP shift. 
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II. INTRODUCTION 
 
 
A. Overview 
 
Dopamine (3,4-dihydroxyphenylethylamine) is a major catecholamine 
neurotransmitter in the brain that plays an important role in brain processes that 
control locomotor activity, reward, attention and cognition (Schultz, 2002).  It is 
synthesized in the neurons from the amino acid tyrosine and stored in the 
synaptic vesicles.  In response to a presynaptic action potential, dopamine is 
released into the synaptic cleft by exocytosis, where it binds to the presynaptic 
and postsynaptic dopamine receptors (Figure 1).  
 
NH2
HO
HO
Dopamine
 
 
 
 The dopamine transporter (DAT) protein mediates the reuptake of 
dopamine into the presynaptic neuron and is primarily responsible for regulating 
the intensity and duration of the dopaminergic neurotransmission.  DAT is 
considered a specific marker of dopaminergic neurons in the central nervous 
system and is found in dendrites, perikarya, axons and nerve endings (Nirenberg 
et al., 1996, 1997).  It is the site of action of psychostimulants such as cocaine, 
and neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  
DAT has been implicated in the etiology of several neurological and psychiatric 
conditions such as Parkinson’s disease, schizophrenia, Tourette’s syndrome, 
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depression, attention deficit hyperactivity disorder (ADHD) and drug addiction 
(Torres, 2006; Bannon, 2005). 
Several dopamine-mediated pathways exist in the brain.  The mesolimbic 
and the mesocortical pathways play key roles in reward assessment.  
Dopaminergic projections from the ventral tegmental area (VTA) to the limbic 
areas (nucleus accumbens, ventral striatum and amygdala) comprise the 
mesolimbic pathway and projections from the VTA to the cortex (medial, 
prefrontal, cingulated and entorhinal cortex) comprise the mesocortical pathway 
(Marsden, 2006).  Other pathways include the nigrostriatal pathway (substantia 
nigra to the caudate putamen) that is associated with locomotor activity and the 
tuberoinfundibular pathway (hypothalamus to the pituitary) that is associated with 
inhibition of prolactin release.  
Cocaine is an alkaloid, extracted from the leaves of the coca plant 
(Erythroxylon coca).  It is the most potent stimulant of natural origin and is 
categorized as a Schedule II drug.  Cocaine inhibits synaptic dopamine uptake 
by interfering with DAT function.  It blocks the reuptake of dopamine into 
presynaptic neurons resulting in increased synaptic dopamine concentrations 
(Figure 1).  Amphetamines are another class of drugs with high potential for 
abuse and addiction.  Methamphetamine is the most commonly used 
amphetamine in the U.S.  Amphetamines increase the synaptic dopamine 
concentrations by a mechanism different from that of cocaine.  They act as DAT 
substrates and compete with dopamine for reuptake into the presyaptic neuron 
(Figure 1).  Amphetamines also cause DAT-mediated dopamine efflux by 
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reversal of the transporter.  The inward transport of amphetamine by the DAT 
increases the number of “inward-facing” transporter binding sites and thereby 
increases the rate of outward transport of dopamine (Kahlig and Galli, 2003).  A 
recent study has implicated a channel-like mode of the DAT in amphetamine-
mediated dopamine efflux (Kahlig et al., 2005).  Amphetamines also act as weak 
bases at the vesicular monoamine transporters (VMAT) and release the vesicular 
dopamine stores, resulting in increased intracellular dopamine concentrations 
that also contribute to reverse transport.  The resultant potentiation of 
dopaminergic neurotransmission in the reward areas of the brain is associated 
with psychostimulant addiction. 
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Figure 1.  Modulation of the dopaminergic neurotransmission by psychostimulants.   
 Dopamine, synthesized in the presynaptic neuron, is stored in the synaptic vesicles.  
Following the arrival of an action potential, dopamine is released into the synaptic cleft by Ca2+ -
mediated exocytosis.  Dopamine binds to the dopamine receptors on the postsynaptic neurons 
and transmits neuronal signals.  Neurotransmission is terminated primarily by reuptake of 
dopamine into the presynaptic neuron via the DAT.  Cocaine blocks the dopamine reuptake and 
increases synaptic dopamine concentrations.  Besides competing with dopamine for reuptake, 
amphetamine promotes dopamine efflux.  
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B. Statement of the Problem 
Cocaine abuse and addiction remains a major problem in the U.S.  
According to the 2004 National Survey on Drug Use and Health, approximately 
34.2 million Americans have experimented with cocaine.  There are more than 
2.5 million chronic cocaine users and around 3 million occasional cocaine users 
in the U.S.  The tolerance factor of cocaine leads to compulsive and addictive 
use within the first few uses.  Even after long periods of abstinence, the memory 
of euphoria associated with cocaine can trigger tremendous craving and relapse 
to drug use.  Cocaine addiction is rapidly progressive and can lead to severe 
medical, psychiatric, and psychosocial problems.  It can even contribute to the 
spread of human immunodeficiency virus (HIV) infections, as a consequence of 
needle sharing.  The euphoria associated with cocaine use is reported to be 
intensely pleasurable and results from the mesolimbic dopamine 
neurotransmission.  The DAT has remained a primary target, with interactions at 
serotonin transporter (SERT) and norepinephrine transporter (NET) playing a 
secondary role, in cocaine abuse and addiction.  There are no effective 
medications currently available to treat cocaine addiction.  Drugs touted as 
therapies for cocaine addiction have proven to be addictive themselves.  It would 
be beneficial to identify a compound that blocks cocaine’s binding to the DAT 
while allowing dopamine reuptake.  No crystallographic or high resolution data 
are available for any of the mammalian neurotransmitter transporter proteins.  
Molecular 3-D models of the DAT have been developed based on sequence 
homology with other protein families and data from site-directed mutagenesis 
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studies.  Therefore, definitive information about the conformation of the DAT or 
the binding sites of the DAT ligands is not available.   
It was previously demonstrated that replacement of the aspartic acid 
residue at position 79 in transmembrane domain (TM) 1 of rDAT with glutamic 
acid (D79E) significantly decreased binding affinities of certain DAT inhibitors, 
while dopamine uptake inhibition potencies (DUIPs) remained unaffected.  Thus, 
the point mutation decoupled the binding affinities of the DAT blockers from their 
respective DUIPs (Wang et al., 2003).  In the course of the above study, it was 
observed that the DUIP of cocaine at wildtype (WT) DAT fluctuated over a wide 
range.  Moreover, the DUIP of cocaine did not match its binding affinity value at 
the WT DAT.  Several studies record a similar loss of correlation between DUIP 
and binding affinity of cocaine at the WT DAT (Pristupa et al., 1994; Eshleman et 
al., 1999; Wang et al., 2003).  Cocaine DUIP values differ by several fold at the 
WT DAT as a function of the assay conditions (Reith and Coffey, 1994; 
Eshleman et al., 1999).  Considering the fact that the same stably transfected 
WT DAT CHO cell line and similar assay conditions were employed in all the 
experiments, similar DUIP values for cocaine would be expected.  One of the 
factors that differed between the assays was the cell passage number.  
Therefore, the nature of the DUIP fluctuation phenomenon was investigated by 
studying the influence of cell passage number on the DUIP of cocaine.  The 
DUIP fluctuation phenomenon was further characterized by studying whether this 
phenomenon extended to the other DAT blockers and DAT substrates.  The 
physiological relevance of the DUIP fluctuation phenomenon was also 
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investigated.  The specific hypothesis to be tested here is that the DUIP of 
cocaine and other DAT ligands at WT DAT fluctuates as a function of cell 
passage. 
Studies were extended further to identify the factors responsible for the 
DUIP fluctuation.  DAT inhibitors may have more than one binding site with 
different affinities at each site (Madras et al., 1989; Boja et al., 1991; Boja et al., 
1992; Rothman et al., 1994; Reith and Coffey, 1994; Gracz and Madras, 1995).  
Two distinct inhibitor-binding DAT conformations or populations may exist and 
the DAT conformation or population responsible for inhibitor high-affinity binding 
may be less responsible for dopamine uptake (Wang et al., 2003).  DAT function 
and trafficking can be regulated by several factors such as protein-protein 
interactions, oligomerization state of the transporter and posttranslational 
modifications.  Several proteins have been shown to interact with the N- and C-
terminus of DAT (reviewed in Torres et al., 2006).  The specific hypothesis to be 
tested here is that intracellular factors interacting with the DAT N- or C-terminus 
are responsible for the DUIP fluctuation of cocaine at the WT DAT. 
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C. Literature Review 
1. Structure of the DAT 
DAT belongs to the Na+/Cl--dependent family of neurotransmitter 
transporters, also referred to as the neurotransmitter:sodium symporter (NSS) 
family.  This family includes the transporters for biogenic amines (norepinephrine, 
serotonin and dopamine), amino acids (GABA, glycine, proline and taurine) and 
osmolytes (betaine and creatinine).  A 620 (human) or 619 (rat) amino acid DAT 
sequence is predicted from cloned cDNAs (Kilty et al., 1991; Giros et al., 1992) 
with an apparent molecular mass of approximately 80,000 daltons (Patel et al., 
1994).  DAT is composed of 12 transmembrane (TM) domains connected by 
alternating intracellular and extracellular loops, with the N- and C-termini located 
on the intracellular side of the membrane (Edvardsen and Dahl, 1994; Nirenberg 
et al., 1996; Hersch et al., 1997).  It has a large second extracellular loop that 
has potential N-glycosylation sites (Vandenbergh et al., 1992; reviewed in Surratt 
et al., 1993).  Stability and plasma membrane trafficking of the DAT is strongly 
influenced by glycosylation (Reith et al., 1997). 
Approaches such as site-directed mutagenesis, chimeric transporters and 
substituted cysteine accessibility method (SCAM) have been extensively 
employed to identify the residues and the domains that participate in substrate 
binding and translocation, and inhibitor binding.  The rat DAT (rDAT) amino acids 
F69, F105, F114, F155, T285, F319, F331, P394, F410, S527, F530, Y533, and 
S538 and the human DAT (hDAT) amino acids V55 and S528 appear to be 
involved selectively with substrate uptake or efflux (reviewed in Volz and Schenk, 
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2005).  Substitution of F69, F331 and F530 by alanine decreases the Km and 
Vmax of dopamine uptake (Lin et al., 1999).  Mutation of P394 to alanine does not 
affect plasma membrane expression, dopamine uptake or WIN 35,428 binding 
but does affect the apparent affinity of dopamine efflux at the DAT (Lin et al., 
2000a, Itokawa et al., 2002).  Substitution of S528 by alanine increases the efflux 
of intracellular dopamine at the DAT without affecting the Km and Vmax of 
dopamine uptake (Chen and Justice, 2000).  Mutation of Y533 has been reported 
to selectively reduce the Vmax of dopamine uptake at the DAT (Itokawa et al., 
2000).  Substitution of V55 by alanine decreases the Km for dopamine uptake at 
the DAT (Lin and Uhl, 2003).  
Na+ and Cl-
 
are transported as co-substrates along with dopamine. W84 
and D313 have been implicated in controlling the ability of Na+ to drive the DAT 
between inward- and outward facing conformations (Chen et al., 2002; Chen et 
al., 2003).  Reports provide evidence for the role of N85 and N466 in Cl-
 
binding 
(Edvardsen and Dahl, 1994; Syringas et al., 2000).  
rDAT amino acids residues W84, F154, P235, F252, S253, P287, F361, 
F456, F542, P544, and P545 and the hDAT amino acids W84, N182 and F168 
may be involved selectively with cocaine analog binding (reviewed in Volz and 
Schenk, 2005).  Substitution of F154, F252, F361, F456, F542 by alanine 
decreases WIN 35,428 binding affinities at the DAT (Itokawa et al., 2000; Lin and 
Uhl, 2002; Lin et al., 1999).  Substitution of F168 by leucine does not affect 
dopamine uptake at the DAT but increases WIN 35,428 binding (Lee et al., 
2000).  The W84A mutation increases WIN 35,428 binding affinity without 
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decreasing dopamine uptake affinity, suggesting that this tryptophan may 
sterically hinder the binding of cocaine analogs at the DAT (Lin et al., 2000b).  
Substitution of P235, P287, P544, P545 by alanine reduces WIN 35,428 binding 
without affecting dopamine uptake affinities (Lin and Uhl, 2002; Lin et al., 2000a).  
Mutation of S253 decreases WIN 35,428 binding affinity without affecting 
dopamine uptake (Itokawa et al., 2000).  Substitution of the N182 by histidine 
does not affect dopamine uptake but does increase WIN 35,428 binding at the 
DAT (Lee et al., 2000). 
 
 
 
Extracellular 
NH2
HOOC
1 2 12 97 10 1186543 
Intracellular 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Topology of the dopamine transporter.   
The dopamine transporter has 12 transmembrane domains with the N- and C-termini 
located on the intracellular side of the membrane.  The large second extracellular loop has 
several sites for glycosylation. 
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Recently, the crystal structure of a bacterial leucine transporter from 
Aquifex aeolicus (LeuTAa), a homologue of the NSS family of transporters, has 
been reported (Yamashita et al., 2005).  This high resolution structure of LeuTAa 
may be very useful in understanding the structure and function of the DAT and 
other mammalian transporters in the NSS family. 
 
2. Mechanism of Dopamine Reuptake 
The dopamine reuptake process is driven by coupling dopamine influx 
with the inward flow of Na+ and Cl- as these ions move down a gradient across 
the cell membrane.  The Na+ gradient is generated by the Na+K+-ATPase (Giros 
et al., 1992).  DAT promotes the transport of dopamine together with Na+ and Cl- 
ions as co-substrates with a stoichiometric ratio of 2:1:1 for 
sodium:chloride:dopamine (Chen and Reith, 2003).  According to the alternating 
access transport mechanism, binding of dopamine, Na+
 
and Cl- to DAT on the 
extracellular side induces a conformational change in the transporter allowing the 
exposure of the binding site to the intracellular side of the membrane.  Dopamine 
and the ions are translocated into the cell and the empty transporter returns to 
the outward facing conformation to initiate another transport cycle.  Reorientation 
of SERT to its outward facing conformation requires binding and outward 
transport of intracellular K+ (Rudnick, 1997).  In addition to the classic substrate 
transport mechanism, transporters can exhibit channel-like activity.  
Simultaneous measurement of dopamine transport-associated current and 
dopamine flux in hDAT-expressing Xenopus oocytes revealed that charge 
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movement during substrate translocation was greater than would be expected for 
a transport mechanism with fixed stoichiometry of 2 Na+ and 1 Cl
-
 ions per 
dopamine molecule.  Besides the transport-associated current, hDAT also 
mediates a constitutive leak current, the voltage and ionic dependencies of which 
differ markedly from those of the transport-associated current (Sonders et al., 
1997).  Recent studies also provide evidence for the existence of a chloride 
channel within the DAT (Ingram et al., 2002; Carvelli et al., 2004).  
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Figure 3.  Dopamine transport via the DAT.   
The Na+K+-ATPase (pink) generates the Na+ and K+ gradients across the plasma 
membrane by moving three Na+ ions out of, for every two K+ ions into, the cell.  The resultant 
transmembrane electric potential (negative inside) leads to Cl- redistribution.  The DAT (green) 
translocates one dopamine molecule along with two Na+ ions and one Cl- ion as co-substrates in 
one transport cycle. 
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3. DAT Inhibitors and Substrates 
Cocaine is a tropane derivative that binds to the dopamine transporter 
and inhibits dopamine uptake.  Cocaine binds to the NET and SERT in addition 
to DAT (Giros and Caron, 1993); serotonergic mechanisms may also play a role 
in cocaine addiction (Rocha et al., 1998).  However, decades of studies have 
established that binding of cocaine to the DAT is primarily responsible for its 
reward and reinforcement effects (Kuhar, 1992; Wise, 1996).  A study employing 
a knockin mouse line carrying a triple mutant (L104V/F105C/A109V) of the DAT 
that is functional but insensitive to cocaine inhibition showed that blockade of the 
DAT is necessary for cocaine reward (Chen et al., 2006).  Cocaine can augment 
dopamine release by mobilizing a synapsin-dependent reserve pool in mice.  
Synapsins are phosphoproteins that interact with the surface of synaptic vesicles 
and segregate synaptic vesicles into the reserve pool.  Secretory vesicles can 
exist as a releasable pool that is available for immediate exocytosis and a 
reserve pool that is spatially segregated and mobilized after prolonged synaptic 
activity (Pieribone et al., 1995; Duncan et al., 2003).  Pretreatment with α-methyl-
p-tyrosine, which depletes the readily releasable pool of dopamine, did not affect 
cocaine’s ability to augment dopamine release.  However, the mechanism by 
which cocaine promotes this synapsin-mediated dopamine release is unknown 
(Venton et al., 2006).   
Several analogs of cocaine have been synthesized.  WIN 35,428 (12 β-
carbomethoxy-3β-(4-fluorophenyl)-tropane) is a cocaine analog that is 
extensively used in DAT binding assays.  Other drugs classified as DAT 
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inhibitors and employed in the present work include mazindol, methylphenidate 
benztropine and the amphetamines.  
Mazindol, an imidazoisoindol derivative, is a tricyclic compound that binds 
to all the monoamine transporters and inhibits substrate uptake.  Studies have 
shown that mazindol exhibits addictive potential (Chait et al., 1987).  It is clinically 
used as an anorexiant for the management of obesity and as an orphan drug for 
the treatment of Duchenne muscular dystrophy.  
Methylphenidate (Ritalin®) is typically used in the symptomatic treatment 
of ADHD.  Its binding affinity for the DAT is almost two times higher than that of 
cocaine and exhibits reinforcing effects similar to cocaine but much milder 
(Bergman et al., 1989).  
Benztropine (3α-diphenylmethoxytropane; Cogentin®) and its analogs 
have high affinity for the dopamine transporter and inhibit dopamine uptake but 
demonstrate behavioral profiles that are distinctive from cocaine.  Benztropine 
differs from cocaine in that it has a diphenylmethoxy group attached to the C-3 
position of the tropane ring (Newman and Kulkarni, 2002).  It is an anticholinergic 
agent that is clinically used in the treatment of Parkinsonism.  Benztropines are 
being extensively studied as potential agents in the treatment of cocaine 
addiction.   
Amphetamines (alpha-methylphenethylamines) are structurally similar to 
dopamine and act as substrates at the dopamine transporter.  Examples of 
amphetamines include (+)-amphetamine, methamphetamine, 3,4-
methylenedioxymethamphetamine (MDMA; ecstasy).  Though amphetamines act 
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at the NET and the SERT, the interaction of amphetamines with the DAT is 
thought to mediate the acute behavioral and reinforcing effects of these 
psychostimulants (Giros et al., 1996).  Amphetamines are used in the treatment 
of ADHD and narcolepsy.  
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Figure 4.  Chemical structures of DAT ligands.   
Cocaine, benztropine, methylphenidate and mazindol are DAT blockers.  Amphetamine is 
a DAT substrate. 
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DAT expression at the cell surface can be regulated by DAT substrates 
and inhibitors.  In both HEK 293 cells expressing hDAT and in rat striatal 
synaptosomes, persistent exposure to dopamine (1 hr) decreased DAT surface 
expression and dopamine uptake activity.  The presence of cocaine during 
dopamine pretreatment prevented the down-regulation of surface DAT.  This 
suggests that dopamine translocation by the DAT is a prerequisite for the 
dopamine-mediated decrease in surface expression of DAT (Chi and Reith, 
2003).  In HEK 293 cells and N2A cells stably expressing hDAT, acute treatment 
with cocaine (≥ 5 min) increased DAT surface expression and dopamine uptake 
activity.  Similar results were obtained with synaptosomes prepared from the 
nucleus accumbens of rats sacrificed 30 minutes after a single cocaine injection 
(Daws et al., 2002; Little et al., 2002).  Persistent exposure to amphetamine (> 20 
min) decreases DAT surface expression and dopamine uptake activity (Gulley et 
al., 2002; Saunders et al., 2000; Zahniser and Sorkin, 2004).  A recent study 
showed that amphetamine increases the DAT surface expression rapidly within 
one minute by recruiting more transporter proteins to the plasma membrane 
(Johnson et al., 2005a). 
 
 
 
 
 
 
 19
4. Regulation of DAT Function and Expression 
DAT Oligomerization 
Increasing evidence suggests that the NSS family members are organized 
into oligomeric complexes.  Coimmunoprecipitation studies employing 
differentially tagged monomers demonstrated that SERT and NET can exist as 
homo-oligomers (Kilic and Rudnick, 2000; Kocabas et al., 2003).  Fluorescence 
resonance energy transfer (FRET) studies provided evidence for the homo-
oligomerization of SERT and GABA transporter (Schmid et al., 2001).  Similar to 
other transporters of the NSS family, DAT also exists as an oligomeric complex 
and oligomerization may be essential for the proper trafficking of the DAT to the 
plasma membrane.  Two loss-of-function DAT mutants (Y335A and D79G) that 
expressed at the cell surface decreased the transport activity of WT DAT without 
affecting its cell surface expression.  This suggested the formation of oligomeric 
complexes of WT DAT with the DAT mutant at the cell surface.  The same study 
showed that an intact leucine heptad repeat in the TM2 domain of the DAT is 
required for oligomerization.  Substitution of amino acids in this repeat by 
mutagenesis resulted in a mutant transporter devoid of uptake activity because of 
its intracellular retention.  This mutant did not inhibit the function of the WT DAT.  
Coimmunoprecipitation and immunofluorescence studies demonstrated that an 
HA epitope-tagged DAT with the leucine heptad repeat mutation did not 
associate with a histidine epitope-tagged WT DAT (Torres et al., 2003).  DAT can 
be oxidatively cross-linked to form homodimers that retain transporter 
functionality; the cross-link is between C306 at the extracellular end of TM6 in 
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each of the two DAT molecules (Hastrup et al., 2001).  The intracellular end of 
TM6 domain of the DAT has a dimerization motif (GV/IXXGV/IXXA/T) that is 
found in other neurotransmitter proteins as well.  This motif was originally 
identified in glycophorin A and was found to be essential for dimerization.  
Mutation of the first glycine of the dimerization motif to valine greatly diminished 
DAT surface expression and completely blocked substrate transport.  Mutation of 
the second glycine completely inhibited surface expression.  Hence, a functional 
dimerization motif in the TM6 domain of the DAT is essential for efficient 
trafficking of the transporter.  The data suggested that the TM6 domain 
contributes to the dimerization interface and that oligomerization may be required 
for cell surface trafficking (Hastrup et al., 2001).  Studies employing FRET 
revealed that DAT exists as oligomers in all cellular compartments in which it is 
localized (Sorkina et al., 2003).  DAT can also exist as tetramers and the TM4 
(C243) domain is present at a homodimeric interface distinct from the TM6 
(C306) interface (Hastrup et al., 2003).  The same study also showed that DAT 
inhibitors such as the cocaine analog MFZ 2-12, benztropine and mazindol 
disallowed the cross-linking of C243 suggesting that these uptake inhibitors are 
not simply neutral blockers but by themselves produce conformational changes 
of the DAT.  Oligomerization of the DAT protein may thus play an important role 
in the proper functioning and trafficking of the transporter.  
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Posttranslational Modifications 
DAT is a heavily glycosylated protein with three or four potential 
consensus sequences (depending on species) for N-linked glycosylation (sugars 
are attached to the amide nitrogen of asparagine residues) in the large second 
extracellular loop.  In general, N-linked glycosylation is essential for proper 
folding and stability of proteins.  Differences in apparent molecular mass of the 
DAT were observed in the striatal tissue of 4, 14 and 60 day old rats.  These 
differences were eliminated by N-deglycosylation suggesting that differential 
glycosylation of DAT occurs during development and aging (Patel et al., 1994).  
Alterations in the glycosylation pattern of DAT were also observed in different 
brain regions (nucleus accumbens versus striatum) and in different species (Lew 
et al., 1991; Patel et al., 1993).  Non-glycosylated DAT does not transport 
dopamine as efficiently as WT DAT.  A sharp reduction in dopamine uptake Vmax 
greater than that accounted for by the fall in surface DAT levels was observed 
with DAT mutants lacking the glycosylation sites (N181, N188 and N205).  
Inhibiting DAT N-glycosylation increased the DUIP of cocaine-like drugs without 
changing their affinity for the DAT (Li et. al., 2004).  Removal of the three hDAT 
glycosylation sites partially impaired DAT trafficking to the plasma membrane, 
suggesting that glycosylation increases DAT surface expression but is not 
essential for trafficking to the cell surface (Torres et al., 2003).  Confocal 
microscopy studies demonstrated that the immunofluorescence of the single 
mutant N181Q was mostly on the cell surface, similar to the WT DAT.  However, 
the immunofluorescence of the double (N181Q, N188Q) and triple mutants 
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(N181Q, N188Q, N205Q) was weaker at the cell surface, with a significant 
amount in the cytosol.  Reversible biotinylation experiments to assess DAT 
endocytosis showed that the double and triple mutants were internalized at a 
faster initial rate, with a significantly reduced surface DAT half-life (Li et al., 
2004).  Despite several studies, the exact role of N-glycosylation in DAT function 
and cell surface expression remains unclear.  It has been shown that N-
glycosylation of SERT is important for homo-oligomerization and protein 
interactions that regulate serotonin uptake (Ozaslan et al., 2003).  Similar to 
SERT, changes in the DAT N-glycosylation pattern may affect DAT-protein 
interactions leading to differences in transporter function and trafficking. 
Analysis of the DAT primary amino acid sequence reveals that the protein 
has several consensus sites for phosphorylation by protein kinase A (PKA), 
protein kinase C (PKC) and Ca2+/calmodulin dependent protein kinase (CaM 
kinase).  To date PKC is the only kinase that has been well characterized as 
contributing to DAT phosphorylation.  Several studies have shown that activation 
of PKC results in reduced DAT activity and surface expression.  Activation of 
PKC by the phorbol ester 4-α-phorbol 12-myristate 13-acetate (PMA) decreased 
the DAT uptake activity in Sf9 cells, evident by the decreased Vmax value.  The 
PMA-mediated reduction in dopamine uptake was antagonized by staurosporine, 
a PKC inhibitor.  Confocal microscopy studies revealed that sequestration of the 
DAT from the cell surface was responsible for the decreased Vmax of dopamine 
transport.  However, the DAT surface density in PMA-treated cells remained 
unchanged.  Treating the cells with a PKC inhibitor promoted an increase in 
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dopamine uptake that was a result of recruitment of the internalized or 
intracellular DAT back to the cell surface.  The data suggested that rapid 
shuttling of the DAT protein between the cell surface and intracellular 
compartments was responsible for the changes in dopamine transport activity in 
response to PKC activation.  Moreover, the differential regulation of the DAT 
activity by a PKC-dependent mechanism was not a result of modifications in the 
DAT catalytic activity (Pristupa et al., 1998).  Another study in PC12 cells stably 
transfected with hDAT demonstrated that the transporter undergoes endosomal 
recycling in response to PKC activation (Melikian and Buckley, 1999).  DAT is 
internalized through a clathrin-mediated and dynamin-dependent mechanism in 
MDCK cells, evidenced by the complete blockade of PMA-mediated translocation 
of DAT with a dominant negative mutant of dynamin 1.  However, this study 
showed that PKC activation results in complete lysosomal degradation of the 
transporter protein, inconsistent with the previous studies (Daniels and Amara, 
1999).  Truncation of the first 22 N-terminal amino acids, including several serine 
residues, nearly abolished detectable phosphorylation of hDAT without affecting 
functional regulation by PKC, suggesting that phosphorylation of these residues 
is not essential for PKC-mediated transporter internalization (Granas et al., 
2003).  The dopamine uptake activity, inhibitor binding and oligomerization of this 
truncated DAT were also not significantly different from the full-length DAT 
(Hastrup et al., 2001).  DAT has a dileucine motif in the third intracellular loop 
and two tyrosine-based motifs, one in the second intracellular loop and one in the 
C-terminus.  These motifs play key roles in the intracellular trafficking of 
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membrane proteins by mediating critical protein-protein interactions.  Mutation of 
the dileucine motif and the two tyrosine-based trafficking motifs in hDAT did not 
significantly affect the PKC-mediated internalization, suggesting that PKC-
mediated internalization does not involve these trafficking motifs (Granas et al., 
2003).  A recent study showed that the PKC-regulated endocytic signal resides in 
the C-terminal region (amino acids 587-591; FREKL) of the DAT (Holton et al., 
2005).  Mitogen-activated protein kinase (MAPK) has also been shown to 
regulate the DAT uptake activity and trafficking.  Striatal synaptosomes and 
epitope tagged hDAT HEK 293 cells exhibited decreased Vmax values without any 
change in Km values when incubated with MAPK kinase (MEK) inhibitors.  
Biotinylation and confocal studies demonstrated that the decrease in Vmax was a 
result of the internalization of surface DAT by clathrin-mediated endocytosis 
(Moron et al., 2003).  
Substrates such as amphetamine and methamphetamine can also 
increase DAT phosphorylation in the absence of exogenous kinase or 
phosphatase.  Cocaine and the PKC inhibitor bisindoylmaleimide were able to 
inhibit methamphetamine-induced DAT phosphorylation (Cervinski et al., 2005).  
Incubation with cocaine, mazindol or methylphenidate did not affect basal or 
PMA-stimulated DAT phosphorylation, but GBR12909 (another DAT blocker) 
strongly suppressed PMA-stimulated phosphorylation (Gorentla and Vaughan, 
2005).  Thus, DAT ligands can have different effects on DAT phosphorylation. 
The only process identified to date as requiring DAT phosphorylation is 
substrate-induced dopamine efflux (Khoshbouei et al., 2004; Johnson et al., 
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2005b).  In HEK 293 cells stably expressing an N-terminal truncated DAT 
(lacking the first 22 amino acids) amphetamine-induced dopamine efflux was 
significantly reduced compared to the full-length DAT.  To investigate the role of 
N-terminal phosphorylation of the DAT in dopamine efflux, all five N-terminal 
serine residues were simultaneously mutated to alanines.  Surprisingly, this 
construct significantly impaired amphetamine-induced dopamine efflux, similar to 
the N-terminal truncated DAT.  In contrast, simultaneous mutation of these same 
five serines to aspartate to simulate phosphorylation resulted in normal 
amphetamine-induced dopamine efflux.  However, the Vmax for dopamine uptake 
remained unaltered in all the mutants.  The study suggests that the N-terminal 
phosphorylation of the DAT is essential for amphetamine-induced dopamine 
efflux but does not affect the inward transport of substrate (Khoshbouei et al., 
2004).  These results could lead to the design and synthesis of new therapeutic 
agents, such as drugs that inhibit amphetamine-induced dopamine efflux without 
affecting dopamine uptake. 
 
Protein Interactions 
Compelling evidence has shown that the DAT undergoes regulated 
trafficking, indicating the possible involvement of transporter-interacting proteins.  
Moreover, several proteins have been implicated in DAT-protein interactions that 
influence the cell surface expression and/or function of the DAT (reviewed in 
Torres, 2006).  Synuclein, a protein that is abundantly expressed in different 
brain regions and highly enriched in presynaptic terminals, has been shown to 
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interact with the hDAT.  The direct protein-protein interaction between hDAT and 
α-synuclein was found to involve the C-terminal region of hDAT (last 15 amino 
acids) and the non-Aβ component (NAC) domain of α-synuclein. Co-expression 
of this protein with hDAT enhanced the dopamine uptake activity and membrane 
clustering of the transporter (Lee et al., 2001).  PICK1, a kinase associated 
protein widely expressed in many tissues including the brain, is a member of a 
family of PDZ domain containing proteins that play an important role in the 
targeting and clustering of several receptors and ion channels.  This protein has 
been shown to interact with the C-terminal region (last 3 amino acids) of the 
DAT.  Overexpression of PICK1 in mammalian cells with hDAT and in cultured 
neurons enhanced the DAT uptake activity due to an increase in the number of 
functional transporters at the cell membrane.  Deletion of the PDZ-binding site in 
DAT impaired the targeting of the mutated transporter to neuronal processes in 
cultured neurons (Torres et al., 2001).  Hic-5, a member of the focal adhesion 
family of adaptor proteins is highly expressed in several tissues including the 
brain.  The amino-proximal portion of the intracellular carboxyl terminus of DAT 
has been shown to interact in vitro and in vivo with the LIM domain of Hic-5.  
Confocal studies demonstrated that Hic-5 colocalizes with DAT on the cell 
membrane.  Hic-5 overexpression downregulates DAT uptake activity by 
decreasing DAT surface expression (Carneiro et al., 2002).  It has been shown 
that syntaxin 1A and the receptor for activated C kinase (RACK1) interact with 
the DAT N-terminal region.  Syntaxin 1A is a major component of the soluble N-
ethylmaleimide-sensitive factor attachement protein receptor (SNARE) complex 
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that regulates neuronal exocytosis; RACK1 is a protein that regulates 
phosphorylation (Lee et al., 2004).  The role of these protein interactions in 
regulation of DAT activity and trafficking has not yet been demonstrated.  
Syntaxin 1A has also been shown to interact with the related GABA transporter 
(GAT1) and the NET resulting in altered surface expression and transport activity 
(Horton and Quick 2001; Sung et al., 2003).  Because DAT is structurally similar 
to these transporters, it is likely that syntaxin also regulates DAT uptake activity 
and trafficking.  Parkin, a protein expressed exclusively in dopaminergic neurons 
is associated with Parkinson’s disease (PD).  Parkin contains a protein-ubiquitin 
E3 ligase that ubiquitinates many substrate proteins to enhance their 
degradation.  Parkin, but not its PD-causing mutants, increased dopamine uptake 
at DAT by increasing its cell surface expression.  Parkin enhanced the 
ubiquitination and degradation of misfolded DAT, so as to prevent it from 
interfering with the oligomerization and cell surface expression of native DAT.  
Thus, it indirectly increased the cell surface expression of the functional DAT 
(Jiang et al., 2004). 
Characterizing the DUIP fluctuation phenomenon of cocaine and other 
DAT ligands and identifying the factor/s responsible for such potency fluctuations 
can help understand better the regulation of DAT activity.  Specific Aim 1 is to 
study whether DAT ligands that inhibit DA uptake show DUIP fluctuations at WT 
DAT as a function of cell age.  It also involves investigation of the physiological 
relevance of the DUIP fluctuation phenomenon.  Specific Aim 2 is to investigate 
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the source of the DUIP fluctuation by assessing the role of the N- or C- terminus 
of the DAT. 
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III. MATERIALS AND METHODS 
 
A.  Materials and Equipment 
 
1. Facilities 
     
Laboratories – Mellon Hall of Science, Rooms 456, 414 and 214  
 
 
2. Cell Lines 
     
Chinese Hamster Ovary (CHO) cells stably transfected with wildtype DAT 
Dr. Surratt’s laboratory at Albert Einstein College of Medicine, NY 
     
COS-7 (African green monkey kidney) cells 
American Type Culture Collection (ATCC), Manassas, VA 
     
N2A (murine neuroblastoma) cells  
Dr. Gnegy’s laboratory at University of Michigan, MI 
 
3. Chemicals and Drugs 
 
[3H]-Dopamine 
Perkin Elmer, Foster City, CA 
 
[3H]-WIN 35, 428 
Perkin Elmer, Foster City, CA 
 
Acetic acid, glacial 
Fisher Scientific, Pittsburgh, PA 
 
Agarose 
Invitrogen Corporation, Carlsbad, CA 
 
Alexa-Fluor 488, goat anti-rat IgG (H+L) 
Molecular Probes, Eugene, OR 
 
Ampicillin sodium salt 
Acros, NJ 
 
Bio-Rad protein assay dye reagent concentrate 
Bio-Rad Laboratories Inc., Hercules, CA 
 
Bovine serum albumin 
Sigma Chemical Co., St. Louis, MO 
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Calcium chloride 
Sigma-Aldrich Co., St. Louis, MO 
Compressed carbon dioxide 
Air Products, Pittsburgh, PA 
 
D-(+)-Glucose 
Sigma-Aldrich Co., St. Louis, MO 
 
dNTP mix 
Stratagene, La Jolla, CA 
 
DH5α cells 
Invitrogen, Carlsbad, CA 
 
Dimethylsulfoxide (DMSO) 
Sigma Chemical Co., St. Louis, MO 
 
Dulbecco’s Modified Eagle Medium (DMEM) 
Hyclone, Logan, UT 
 
Dulbecco’s Phosphate Buffered Saline (DPBS) Ca/Mg-free 
Cambrex Bioscience Walkersville Inc., MD 
 
EcoR1 
Invitrogen, Carlsbad, CA 
 
EDTA 
Sigma-Aldrich Co., St. Louis, MO 
 
Ethanol 200 proof 
Pharmaco Products Inc., Brookfield, CT 
 
Ethanol, HPLC grade 
Acros, NJ 
 
Ethidium bromide 
Fisher Scientific, Pittsburgh, PA 
 
F-12 Nutrient Mixture 
Hyclone, Logan, UT 
 
Fetal bovine serum 
Hyclone, Logan, UT 
 
G-418 sulfate 
Clontech Laboratories Inc., CA 
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L-Glutamine 
Invitrogen, Carlsbad, CA 
 
Glycerol 
Fisher Scientific, Pittsburgh, PA 
 
Glycine 
Sigma-Aldrich Co., St. Louis, MO 
 
Goat serum 
Biomeda Corporation, Foster City, CA 
 
GVA mounting solution 
Zymed, San Francisco, CA 
 
HEPES free acid 
MP Biomedicals Inc., Solon, OH 
 
HBSS/modified 
Hyclone, Logan, UT 
 
Isopropanol (DNase, RNase and protease free) 
Fisher Scientific, Pittsburgh, PA 
 
Kpn1 
Invitrogen, Carlsbad, CA 
 
LB agar 
Fisher Scientific, Pittsburgh, PA 
 
LB broth 
Fisher Scientific, Pittsburgh, PA 
 
MAB369 Rat anti-Dopamine Transporter 
Chemicon International, Temecula, CA 
 
Methanol, HPLC grade 
Fisher Scientific, Pittsburgh, PA 
 
Opti-MEM I 
Invitrogen, Carlsbad, CA 
 
Paraformaldehyde 
Sigma Chemicals Co., St. Louis, MO 
Penicillin-Streptomycin 
Gibco-BRL, Grand Island, NY 
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PolyFect Transfection Reagent 
Qiagen Inc., Valencia, CA 
 
Polymerase, Pfu Turbo 
Stratagene, La Jolla, CA 
 
Potassium chloride 
Sigma-Aldrich Co., St. Louis, MO 
 
Potassium phosphate, monobasic 
Sigma Chemical Co., St. Louis, MO 
 
Primers 
Sigma Genosys, The Woodlands, TX 
 
Rhodamine phalloidin 
Molecular Probes, Eugene, OR 
 
RNase A (DNase free) 
Fisher Scientific, Pittsburgh, PA 
 
SOC media 
Invitrogen, Carlsbad, CA 
 
ScintiSafe scintillation fluid 
Fisher Scientific, Pittsburgh, PA 
 
Sodium Chloride 
Sigma-Aldrich Co., St. Louis, MO 
 
Sodium Hydroxide 
Fisher Scientific, Pittsburgh, PA 
 
Sodium Hydroxide 2N solution 
Fisher Scientific, Pittsburgh, PA 
 
Sodium Hydroxide 12N solution 
Fisher Scientific, Pittsburgh, PA 
 
Sodium lauryl sulfate 
Sigma Chemical Co., St. Louis, MO 
T4 DNA ligase 
Invitrogen, Carlsbad, CA 
 
Tris-EDTA buffer (DNase, RNase and protease free) 
Acros, NJ 
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Tris free base 
Fisher Scientific, Pittsburgh, PA 
 
Tris-HCl salt 
Sigma Chemical Co., St. Louis, MO 
 
Triton X-100 
Acros, NJ 
 
Trypsin-EDTA 10X 
Gibco-BRL, Grand Island, NY 
 
Xba1 
Gibco-BRL, Grand Island, NY 
 
 
4. Kits 
 
Gel extraction kit 
Qiagen Inc., Valencia, CA 
 
PCR purification kit 
Qiagen Inc., Valencia, CA 
 
Plasmid miniprep kit 
Stratagene, La Jolla, CA 
 
Plasmid purification kit (maxiprep) 
Qiagen Inc., Valencia, CA 
 
 
5. Other Materials 
 
Cell culture flasks, 75 cm2
Corning Inc., NY 
 
Cell culture grade water 
Hyclone, Logan, UT 
Cell scraper, disposable 
Fisher Scientific, Pittsburgh, PA 
 
Centrifuge tubes, 15 ml 
Corning Inc., NY 
 
Cryogenic vials, 1.5 ml 
Corning Inc., NY 
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Culture tubes, disposable 
Fisher Scientific, Pittsburgh, PA 
 
Falcon tubes, 14 ml 
Fisher Scientific, Pittsburgh, PA 
 
Falcon tubes, 50 ml 
Fisher Scientific, Pittsburgh, PA 
 
Filter unit, sterile 
Millipore Corporation, MA 
 
Glass microscope coverslips (# 1) 
Fisher Scientific, Pittsburgh, PA 
 
Glass microscope slides 
Fisher Scientific, Pittsburgh, PA 
 
Microcentrifuge eppendorf tubes, 1.5 ml 
Fisher Scientific, Pittsburgh, PA 
 
Parafilm 
Fisher Scientific, Pittsburgh, PA 
 
Pasteur pipettes, disposable 
Fisher Scientific, Pittsburgh, PA 
 
Pipette tips, disposable Redi-Tips TM (1, 10, 200, 1000 µl) 
Fisher Scientific, Pittsburgh, PA 
 
Polaroid film 
Polaroid Corporation, Cambridge, MA 
 
Polypropylene tubes 
Fisher Scientific, Pittsburgh, PA 
 
 
Respirator 
Fisher Scientific, Pittsburgh, PA 
 
   Scintillation vials  
Fisher Scientific, Pittsburgh, PA 
 
Serological pipettes, sterile disposable (5, 10, 25 ml) 
Fisher Scientific, Pittsburgh, PA 
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Syringes 10 ml, sterile 
Fisher Scientific, Pittsburgh, PA 
 
Thermowell PCR tubes 
Corning Incorporated, NY 
 
Tissue culture plates, sterile (6-well) 
Fisher Scientific, Pittsburgh, PA 
 
 
6. Equipment 
 
Analytical balance 
Mettler Toledo Inc., OH 
 
Bottletop dispenser 
Brinkmann Instruments Inc., NY 
 
Cell culture incubator 
Forma Scientific, MA 
 
Centrifuge Model 228 
Fisher Scientific, Pittsburgh, PA 
 
Centrifuge 5415 C 
Eppendorf Scientific Inc., NY 
 
Centrifuge 5810 R 
Eppendorf Scientific Inc., NY 
 
Confocal laser microscope Leica TCS-SP2 
Leica Microsystems Inc., PA 
 
Dispenser eppendorf (50 ml) 
Brinkmann Instruments Inc., NY 
 
 
Electrophoresis Power Supply 
Life Technologies Inc., Gaithersburg, MD 
 
Horizontal Gel Electrophoresis System 
Life Technologies Inc., Gaithersburg, MD 
 
Inverted microscope Olympus CK40 
Fisher Scientific, Pittsburgh, PA 
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Isotemp Incubator 
Fisher Scientific, Pittsburgh, PA 
 
Lab freezers and refrigerators 
Forma Scientific, MA 
 
Liquid Nitrogen tank 
 
Liquid Scintillation Analyzer 
Packard Instruments Co., CT 
 
Millipore Milli-Q and Elix 
Millipore Corporation, MA 
 
Mixer (Style: 37600) 
Thermolyne Corporation, IA 
 
NapFLOW Laminar air flow unit 
Fisher Scientific, Pittsburgh, PA 
 
ORBIT Shaker 
Lab-line Instruments Inc., IL 
 
PCR Mastercycler 
Eppendorf Scientific Inc., NY 
 
pH meter AB15 
Fisher Scientific, Pittsburgh, PA 
 
Pipet-aid 
Drummond Scientific Co., Broomall, PA 
 
Pipetman (P-2, P-10, P-20, P-100, P-200, P-1000) 
Mettler Toledo Company, Woburn, MA 
 
Polaroid Gelcam 
Polaroid Corporation, Cambridge, MA 
Stir plate Nuova II 
Thermolyne Corporation, IA 
 
 
Universal Vacuum System UVS 400 
Savant Instruments Inc., NY 
 
UV Transilluminator M-26 
UVP Inc., Upland, CA 
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UV-Visible Spectrophotometer DU 530 
Beckman Instruments Inc., Fullerton, CA 
 
Vacuum pressure pump  
Barnant Co., IL 
 
Vertex-2 Genie 
Scientific Industries Inc., NY 
 
Water bath 180 series 
Precision Scientific, Winchester, VA 
 
Water bath Iso TEMP 205 
Fisher Scientific, Pittsburgh, PA 
 
Weighing scale 
Denver Instruments Co., CO 
 
 
7. Computer Software 
 
Adobe Acrobat Reader 7.0 
Adobe Systems Inc. 
 
Adobe Acrobat Writer 
Adobe Systems Inc. 
 
ChemDraw 
CambridgeSoft Corporation, Cambridge, MA 
 
GraphPad Prism 3.0 
GraphPad Software, San Diego, CA 
 
 
Microsoft Office Word & Excel 2003 
Microsoft Corporation 
 
 
 
 
 
 
 
 
 
 
 38
B.  Methodology and Procedures 
 
 
1. Cell Culture 
 CHO-K1 cells stably transfected with WT DAT were grown in F-12 media 
supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin ,100 
units/ml streptomycin and 100µg/ml G-418.  COS-7 cells were cultured in 
“complete” DMEM media (supplemented with 10% FBS, 100 units/ml penicillin, 
100 units/ml streptomycin and 20 mM L-glutamine).  N2A cells were grown in 
“complete” OPTI-MEM I media (supplemented with 10% FBS, 100 units/ml 
penicillin and 100 units/ml streptomycin).  All cell types were grown as 
monolayers in 75 cm2 flasks at 37ºC and 5% CO2 and subcultured twice weekly 
or every 3 days.  For subculturing the WT DAT CHO and COS-7 cells, the 
exhausted media in the flask was aspirated and the confluent adherent cells 
were washed once with 10 ml Hanks buffered salt solution (HBSS).  To detach 
the cells from the flask, 3ml trypsin-EDTA was added and swirled to cover the 
cell monolayer completely.  Two ml of the trypsin-EDTA was aspirated and the 
flask was returned to the incubator.  The cells were checked every 2 minutes for 
detaching from the flask.  The detached cells were resuspended in 9 ml complete 
media to inactivate the trypsin.  Two ml of the cell suspension was transferred 
into a new labeled flask containing 18 ml of complete media.  The flask was 
capped and the cells evenly suspended by gently swirling the flask.  The flask 
was placed in the incubator and the cells were allowed to grow till the next 
subculture.  For subculturing the N2A cells, the exhausted media in the flask was 
removed and 3 ml of trypsin-EDTA was added.  Two ml of the trypsin-EDTA was 
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removed from the flask and the cells were incubated with the remaining 1 ml 
trypsin-EDTA at room temperature (inside the sterile laminar air flow unit) for 1-2 
minutes until the cells detached from the flask.  The cells were resuspended in 9 
ml of complete media to inactivate the trypsin.  The cell suspension was 
transferred into a sterile 15 ml tube and centrifuged for 4 minutes.  The 
supernatant was decanted and cell pellet was resuspended in 10 ml complete 
media.  Two ml of the cell suspension was transferred into a new labeled flask 
containing 18 ml of complete media.  The flask was capped and the cells evenly 
suspended by gently swirling the flask.  The flask was moved to the incubator 
and the cells were allowed to grow till the next subculture. 
 
2. Polymerase Chain Reaction and Plasmid Preparation 
The N- and C-terminus fragments of rat WT DAT were generated and 
amplified by Polymerase Chain Reaction.  Primers were designed for the N- and 
C-terminus fragments with Kpn1 and EcoR1 restriction enzyme sites on the 5' 
ends of the sense and antisense primers respectively.  The sequences                          
of primers designed for the N-terminus (first 68 nucleotides) of WT DAT                          
were: 5'-ATATATGGTACCATGAGTAAGAGCAAATGCTCCGTGGGAC-3' and 5'-
ATATATGAATTCATCAATTTTCTTGCTCCAGGTCTCCCG-3'.  The sequences 
of the primers designed for the C-terminus fragment (last 43 nucleotides) of WT 
DAT were: 5'-ATATATGGTACCTACAAGTTCTGCAGCCTGCCGGGGTC-3' and 
5'-ATATATGAATTCCAGCAACAGCCAGTGACGCAGCG-3'.  The primers were 
synthesized by Sigma Genosys Inc., U.S.A.  WT DAT in Bluescript vector was 
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used as the template.  The reaction tubes were prepared with the calculated 
quantities of template, primers, dNTP mix and Pfu Turbo DNA Polymerase.  The 
reaction was set for 25 cycles with denaturation of the double stranded template 
DNA at 95ºC for 45 seconds, annealing of the primers to the single stranded 
DNA at 55ºC for 45 seconds and extension of the new DNA strand at 72ºC for 2 
minutes.  Agarose gel electrophoresis was employed to confirm the right sizes of 
the PCR products.  The gel purified PCR products were digested with the 
restriction enzymes and ligated into pc3DNAGFP vector such that the DAT N- 
and C- terminus peptide fragments would be expressed with GFP tag attached to 
the C-terminus of the peptide when transfected into mammalian cells.  The 
ligation product was transformed into DH5α cells by heat shock method and the 
cells were plated on ampicillin supplemented agar petri plates and incubated at 
37ºC for 16 hours.  The bacterial colonies were used to inoculate 5 ml of LB broth 
and the bacteria were allowed to grow for 16 hours.  The supercoiled DNA was 
extracted using the Stratagene mini-prep kit and after confirming the right DNA 
sequence (sequencing facility, University of Pittsburgh) and size (by digesting 
with restriction enzymes and agarose gel electrophoresis), 200 ml LB broth was 
inoculated to produce large amounts of the plasmid of interest.  The DNA 
concentration was estimated by measuring the absorbance at 260 nm and purity 
was determined by the ratio of the absorbance values at 260 and 280 nm.  
Plasmid DNA with a ratio of greater than or equal to 1.7 was considered pure 
enough for performing transient transfections.  The pcDNA3 plasmids encoding 
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human DAT (hDAT) and del-20 hDAT (hDAT lacking the first 20 amino acids) 
were kindly provided by Dr. Gonzalo E. Torres, University of Pittsburgh. 
 
3. Cell Transfections 
Stably transfected WT DAT CHO cell line employed in the study was 
developed in Dr. Surratt’s laboratory at Albert Einstein College of Medicine, NY.  
Lipofectamine transfection method and G-418 mediated stable transfectant 
selection was employed for preparing the stable cell line. 
Polyfect method with modification of the manufacturer’s protocol was 
employed for transiently transfecting COS-7 cells.  The day before transfection, 4 
х 105 cells were seeded in 6-well plates and incubated at 37ºC and 5% CO2 such 
that the cells would be 50-80% confluent on the day of transfection.  Prior to 
transfection, the growth media in the plates was gently aspirated, the cell 
monolayers were washed with 1 ml phosphate buffered saline (PBS), 1.5 ml 
fresh complete media was added to the cells in each well, and the cells were 
maintained at 37ºC and 5% CO2 until the addition of transfection complexes.  For 
preparing the transfection mixture for the cells in one well, 1.5 µg DNA was 
added to 100 µl media (containing no serum, proteins, or antibiotics) in a sterile 
tube and mixed by vortexing for few seconds.  Ten µl Polyfect reagent was 
added to the DNA solution, mixed by vortexing for 10 seconds and incubated for 
9 minutes at room temperature to allow complex formation.  Six hundred µl 
complete media was added to the reaction tube containing transfection 
complexes and mixed by pipetting up and down twice.  The total volume of the 
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transfection mix was transferred immediately to the cells in a single well and the 
plate was gently swirled to ensure uniform distribution of the complexes.  The 
cells were then incubated at 37ºC and 5% CO2 and pharmacological assays were 
performed 24 - 48 hours after transfection.  When performing transient 
transfections of cells in more than one well, all the volumes were scaled up 
appropriately.  In experiments manipulating the DAT expression levels, 
suboptimal amounts of plasmid were employed.  Vector plasmid was employed 
to ensure that each well received the same amount of total DNA.  In experiments 
requiring co-transfection of different plasmids, the required amounts of each 
plasmid were calculated and vector plasmid was employed to ensure that each 
treatment supplied the same amount of total DNA to the cells. 
Transient transfections with N2A cells were conducted via the modified 
calcium phosphate method (Graham and van der Eb, 1973).  The day before 
transfection, cells were seeded in 6-well plates and incubated at 37ºC and 5% 
CO2 such that the cells would be 30-40% confluent on the day of transfection.  
Four hours prior to transfection, the media in the wells was replaced with 2 ml 
fresh media.  All the reagents were filter sterilized.  The transfection procedure 
involved preparing 2 tubes, with the contents of one tube added slowly to the 
other.  Preparing the first tube involved addition of Millipore water, plasmid DNA, 
10х Tris-EDTA (TE) buffer pH 8.0 and 0.5 M CaCl2 in the order listed and mixing 
by gently vortexing.  The second tube contained 2x HEPES – buffered saline 
(HBS) solution.  The contents of first tube were added to the second tube 
dropwise with continuous gentle vortexing and incubated at room temperature.  
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Soon after the DNA complexes started forming, the mixture was pipetted up and 
down thrice to ensure a uniform suspension and to reduce the particle size of the 
complexes.  Two hundred µl of the above mixture was added to each well and 
the plate was gently swirled to ensure uniform distribution.  The following day, the 
transfection mixture in each well was replaced with 2 ml fresh media.  The cells 
were used for the pharmacological assays 48 hours later.  In experiments 
manipulating the DAT expression levels, suboptimal amounts of plasmid were 
employed and same amount of total DNA was added to the cells by employing 
vector plasmid.  In experiments requiring co-transfection of different plasmids, 
the required amounts of each plasmid were calculated and vector plasmid was 
employed to ensure that each treatment supplied the same amount of total DNA 
to the cells. 
 
4. [3H]-Dopamine Uptake Assays 
All [3H]-dopamine uptake assays were performed with cells grown in 6-well 
plates.  For performing simple [3H]-dopamine uptake assays, cell monolayers 
were washed 2 х 1 ml with “KRH buffer” (25 mM HEPES, pH 7.3, 125 mM NaCl, 
4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5.6 mM glucose) 
supplemented with 50 mM ascorbic acid (KRH/AA), incubated with 750 µl 
KRH/AA buffer (total uptake) or 10 µM mazindol (non-specific uptake) for 10 
minutes, followed by incubation with10 nM [3H]-dopamine for an additional 5 
minutes.  Uptake was quenched by washing the cell monolayers 2 х 1 ml with 
KRH/AA buffer.  Cell monolayers were solubilized by incubating with 1 ml of 1% 
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SDS at room temperature for 1 hour with gentle shaking.  The cell lysates were 
transferred into scintillation vials containing 5 ml of ScintiSafe fluid and the 
incorporated radioligand was determined by employing a liquid scintillation 
counter.  The specific uptake was calculated as the difference between total and 
non-specific uptake, i.e. uptake in the presence and absence of 10 µM mazindol. 
For performing [3H]-dopamine uptake inhibition assays, cell monolayers 
were washed 2 х 1 ml with KRH/AA buffer, incubated with 750 µl DAT blocker or 
substrate for 10 minutes, followed by incubation with10 nM [3H]-dopamine for an 
additional 5 minutes.  The uptake inhibition assays included nonradioactive DAT 
inhibitors or substrates at the following concentration ranges: cocaine, 1nM – 100 
µM; benztropine, 1 nM – 30 µM; mazindol, 0.1 nM – 10 µM; methylphenidate 3 
nM – 30 µM; (+)-amphetamine, 1 nM – 10 µM.  Uptake was quenched by 
washing the cell monolayer 2 х 1 ml with KRH/AA buffer.  Cell monolayers were 
solubilized by incubating with 1 ml of 1% SDS at room temperature for 1 hour 
with gentle shaking.  The cell lysates were transferred into scintillation vials 
containing 5 ml of ScintiSafe fluid and the incorporated radioligand was 
determined by employing a liquid scintillation counter.  Non-specific uptake was 
determined by using 10 µM mazindol, or 30 µM cocaine if mazindol was the drug 
being assessed.  The specific uptake was calculated as the difference between 
total and non-specific uptake.  The IC50 values for [3H]-dopamine uptake 
inhibition were determined with GraphPad Prism 3.0. 
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5. Ligand Binding Assays 
All ligand binding assays were performed with cells grown in 6-well plates.  
All [3H]-WIN 35,428 binding inhibition assays were performed exactly as 
described above for the dopamine uptake inhibition assays except that 1 nM [3H]-
WIN 35,428 was used in place of [3H]-dopamine, and the cells were incubated 
with a mixture of radioligand and the nonradioactive competitor for 15 minutes.  
One nM final concentration of [3H]-WIN 35,428 was achieved by adding 10 nM 
solution to each dilution of the nonradioactive competitor.  The concentration 
ranges of the different nonradioactive DAT inhibitors or substrates employed in 
the binding assays were as indicated above for the dopamine uptake inhibition 
assays.  Non-specific uptake was determined by using 10 µM mazindol or 30 µM 
cocaine if mazindol was the drug being assessed.  [3H]-WIN 35,428 saturation 
binding assays were performed by incubating the cells with a mixture of 
nonradioactive WIN 35,428 (1nM – 10 µM) and 1 nM [3H]-WIN 35,428 for 15 
minutes.  Data were analyzed with GraphPad Prism 3.0 to obtain Kd, Ki and Bmax 
values. 
 
6. Immunocytochemistry and Confocal Microscopy 
Immunocytochemistry and confocal microscopy was performed with COS-
7 cells.  Cells were seeded on methanol treated coverslips in 6-well plates such 
that they would be 40-80% confluent the next day.  Polyfect reagent was used to 
perform the transient transfections with the cDNA plasmids.  Forty-eight hours 
after transfection, the cells were washed thrice with PBS and fixed using 4% 
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paraformaldehyde solution in PBS at room temperature for 15 minutes.  The 
fixed cells were washed three times with PBS and incubated with blocking-
permeabilizing solution (5% goat serum, 0.5% BSA, 0.1% Triton X-100 in PBS 
solution) for 45 minutes.  The cells were next washed thrice with BSA buffer 
(0.5% BSA solution in PBS) and incubated with rat monoclonal anti-DAT 
antibody at 1:1000 dilution for 1 hour.  After washing five times with BSA buffer to 
remove the excess anti-DAT antibody, the cells were incubated with secondary 
antibody (goat anti-rat Alexa Fluor 488) at 1:500 dilution and rhodamine 
phalloidin at 1:250 dilution for 1 hour.  When transfections were performed with 
plasmids coding GFP, the antibody incubation steps were eliminated and cells 
were incubated with rhodamine phalloidin at 1:250 dilution for 1 hour.  After three 
washes in BSA buffer and three washes in PBS, the coverslips were slightly air-
dried and mounted on slides using GVA mounting solution.  The slides were left 
in dark at 4 ºC overnight to dry completely.  All the fluorophores were visualized 
using a Leica TCS-SP2 confocal laser microscope with an oil immersion 100x 
objective.  Alexa 488 and GFP were excited at 488 nm with an argon/kypton 
laser and emission photons from 500 – 600 nm were accumulated by the 
photomultiplier tube.  Rhodamine phalloidin was excited at 543 nm with a 
helium/neon laser and emission photons from 550 to 650 nm were accumulated.  
The fluorophores were detected separately and overlay images were generated 
automatically by the imaging software.  In experiments where quantification of 
the images was performed, 10 individual cells were selected randomly by 
screening the whole slide.  All scan related and in-line parameters except Z-level 
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were fixed when acquiring images for each fluorophore.  Images were quantified 
using the histogram quantification tool of the Leica Confocal Software.  The 
mean intensity values for ten different regions on the cell membrane having the 
same number of pixels and area were obtained.  The average intensity of the ten 
different regions on the cell membrane was calculated and the mean intensity for 
each fluorophore was determined by averaging the mean intensities of ten 
different cells.  For counting the number of cells transfected, ten different fields 
were selected randomly by screening the whole slide using 20x objective. 
 
7. Protein Assays 
Protein assays were performed on CHO cells stably transfected with WT 
DAT, and COS-7 and N2A cells transiently transfected with WT DAT.  For all the 
experiments that required protein content estimation, two wells were reserved for 
determining the protein content.  The protein assays were performed as follows: 
the adherent cell monolayers were washed 2 x 1 ml with PBS, the cells were 
lysed with 0.5 ml 0.2 N sodium hydroxide solution, gently scraped with a cell 
scraper and incubated at 4ºC with gentle shaking for 1 hour.  The cell lysates 
were transferred into Eppendorf tubes and stored at -20ºC until the protein 
content was estimated.  All protein assays were performed using the Bradford 
method.  Bovine serum albumin (BSA; 1 mg/ml stock solution) was used as the 
protein standard for generating the protein standard curve.  Six different known 
concentrations of protein were prepared by diluting 1, 2, 3, 4, 5 and 6 µl of BSA 
stock solution to 800 µl with sterile water to achieve final concentrations of 1, 2, 
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3, 4, 5 and 6 µg/ml respectively after the final addition of 200 µl BioRad reagent.  
Tubes for the test samples were also prepared simultaneously by adding 20 µl 
test sample to sterile water to obtain a final volume of 800 µl.  Two hundred µl 
BioRad reagent was then added to all the known and test sample tubes.  The 
tubes were vortexed for 10 seconds and incubated at room temperature for 10 
minutes.  The absorbance values were determined at 595 nm using UV-Visible 
spectrophotometer.  Protein standard curve was obtained by plotting the 
absorbance values of the known samples against the amount of protein in each 
sample using Microsoft Excel.  The amount of protein in each of the test samples 
was calculated from the standard curve. 
 
8. Statistics 
Statistical significance was calculated using GraphPad Prism 3.0.  
Statistical significance among three groups was determined using one-way 
analysis of variance with Newman-Keuls post hoc test.  Two-group comparisions 
were made using a two-tail Student’s t test. 
 
 
 
 
 
 
 
 49
IV. RESULTS 
 
A. Effects of cell age and DAT cell surface expression on dopamine uptake 
inhibition potencies of classical DAT ligands. 
 
It was empirically observed for years that the DUIP of cocaine at WT DAT 
was not static and changes in cocaine DUIP occurred within the same cell line 
when assays were performed employing different passages of cells.  In an 
attempt to address this issue, the present study investigated the effect of cell 
state on DUIP fluctuation of cocaine and the trend this fluctuation follows with 
increasing cell passage number.  Different passages of stably transfected WT 
DAT CHO cells were employed and passages 9 – 20, 25 – 36 and 40 – 54 were 
classified as “low”, “medium” and “high” respectively.  All uptake and binding 
assays were performed in parallel and under identical conditions.  A decrease in 
the DUIP of cocaine at WT DAT was observed with increasing cell passage 
number (Figure 5 and Table 1).  The IC50 value for inhibition of [3H]-dopamine 
uptake at low passage was about 2-fold less when compared to high passage 
(Table 1).  On the other hand, the apparent binding affinity of cocaine did not 
vary with cell passage, evidenced by the unchanging Ki value from inhibition of 
[3H]-WIN 35,428 binding assays (Figure 5 and Table 1).  The study was further 
expanded to test if this trend was exhibited by other classical DAT blockers.  
Mazindol, methylphenidate and benztropine were the other DAT inhibitors tested 
and a trend similar to cocaine for the DUIP was observed for these drugs with 
cell passage (Table 1).  The study also investigated if this property was exhibited 
by DAT substrates such as (+)-amphetamine.  Interestingly, no significant 
fluctuation in DUIP was observed for amphetamine (Figure 6 and Table 1).  
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Similar to that of cocaine, the apparent binding affinities of the other DAT 
blockers and amphetamine did not vary with cell passage (Table 1).  
 
 
B
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Figure 5.  Cocaine and mazindol (DAT blockers) inhibition of [3H]-dopamine uptake and 
[3H]-WIN 35,428 binding at WT DAT CHO cells.   
Cocaine inhibition of [3H]-dopamine uptake (Panel A), cocaine inhibition of [3H]-WIN 
35,428 binding (Panel B), methylphenidate inhibition of [3H]-dopamine uptake (Panel C) and 
methylphenidate inhibition of [3H]-WIN 35,428 binding (Panel D) at different passages of WT DAT 
CHO cells.  Passages 9 – 20, 25 – 36 and 40 – 54 were classified as “low”, “medium” and “high”, 
respectively.  Uptake and binding experiments for each drug at different passages were 
performed in parallel and under identical conditions.  The data are representative of at least 3 
independent experiments. 
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The ratios of dopamine uptake inhibition potency-to-binding affinity for the 
different DAT ligands at the different passages of WT DAT CHO cells were 
calculated.  (Table 2; Ki values (not shown) and IC50 values for [3H]-dopamine 
uptake inhibition in Table 1 were essentially identical, allowing direct comparison 
of uptake and binding inhibition constants). 
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Figure 6.  (+)-Amphetamine (DAT substrate) inhibition of [3H]-dopamine uptake and [3H]-
WIN 35,428 binding at WT DAT CHO cells.   
Amphetamine inhibition of [3H]-dopamine uptake (Panel A) and amphetamine inhibition of 
[3H]-WIN 35,428 binding (Panel B) under identical conditions at different passages of WT DAT 
CHO cells.  Passages 9 – 20, 25 – 36 and 40 – 54 were classified as “low”, “medium” and “high”, 
respectively.  The data are representative of at least 3 independent experiments.  
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Table 1.  Dopamine uptake inhibition potencies and binding affinities of DAT ligands at WT 
DAT CHO cells as a function of cell passage number.   
IC50 and Ki values were derived from experiments incubating the stably-transfected cells 
with nonradioactive DAT inhibitors in the presence of [3H]-dopamine and [3H]-WIN 35,428, 
respectively, at 22ºC in KRH buffer.  Passages  9 -20, 25 - 36 and 40 - 54 were classified as 
“low”, “medium” and “high”, respectively.  Mean ± SEM for at least 3 independent experiments. 
 
 
 Cell Passage 
 
 Low Medium High 
[3H]-DA uptake 
inhibition 
 IC50 (nM)  
Cocaine 719 ± 94 1055 ± 52 1503 ± 127a
Mazindol 44 ± 4 74 ± 5 93 ± 17a
Methylphenidate 352 ± 17 640 ± 22 662 ± 45a
Benztropine 236 ± 40 395 ± 45 413 ± 27a
(+)-Amphetamine 671 ± 88 756 ± 86 906 ± 39 
 
[3H]-WIN 35,428 
inhibition 
 Ki (nM)  
Cocaine 179 ± 22 197 ± 22 251 ± 28 
Mazindol 15 ± 2 19 ± 2 20 ± 2 
Methylphenidate 74 ± 7 72 ± 5 85 ± 6 
Benztropine 78 ± 6 85 ± 9 92 ± 10 
(+)-Amphetamine 524 ± 31 478 ± 52 557 ± 78 
 
[3H]-WIN 35,428 binding    
Kd (nM) 17 ± 1 17 ± 2 18 ± 1 
Bmax (pmol/mg) 9 ± 2 11 ± 2 19 ± 3a
 
 
aP < 0.05 versus low passage cells for that assay (one-way ANOVA, Newman-Keuls post hoc 
test) 
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[3H]-WIN 35,428 saturation binding assays demonstrated that there was 
an increase in the surface expression of WT DAT in CHO cells with increasing 
cell passage number, evidenced by the increased Bmax value for [3H]-WIN 35,428 
binding at high passage cells.  However, the binding affinity of [3H]-WIN 35,428 
remained unchanged at the different cell passages (Table 1). 
 
 
Table 2.  Ratios of dopamine uptake inhibition potency-to-binding affinity for DAT ligands 
at WT DAT CHO cells as a function of cell passage number.   
Ratios were calculated using the IC50 values for inhibition of [3H]-dopamine uptake and Ki 
values for inhibition of [3H]-WIN 35,428 binding in Table 1.  Ki values (not shown) and IC50 values 
for [3H]-dopamine uptake inhibition were essentially identical, allowing direct comparison of 
uptake and binding inhibition constants. 
 
 
 
 DUIP:Affinity Ratio 
 Cell Passage 
 Low Medium High 
Cocaine 4.0 5.3 5.9 
Mazindol 2.9 3.8 4.7 
Methylphenidate 4.8 8.8 7.8 
Benztropine 3.0 4.6 4.5 
(+)-Amphetamine 1.3 1.6 1.6 
 
 
 
To address whether the decrease in DUIP of cocaine at high passage WT 
DAT CHO cells was simply a result of increase in DAT levels, assays were 
performed manipulating the cell density (% confluence) of WT DAT CHO cells.  
The monolayer was defined as 100% confluent when all cells appeared to 
contact neighboring cells so as not to leave open spaces on the culture plate. 
Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding assays 
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performed on 20%, 100% and 150% confluent monolayers suggested that cell 
density had no effect on either cocaine DUIP or binding affinity (Reference: 
Structural determinants for substrate and inhibitor recognition by the dopamine 
transporter, Dissertation of Okechukwu T. Ukairo, Duquesne University).  To 
further investigate the DUIP shift of cocaine, naive COS-7 cells were transiently 
transfected with varying amounts of a cDNA plasmid encoding the WT DAT to 
achieve different DAT expression levels with respect to individual cells.  The 
amounts of plasmid employed in the transfections were 25, 50 and 100% of what 
is optimal.  [3H]-WIN 35,428 saturation binding analysis confirmed that Bmax 
values shifted in accordance with manipulation of plasmid level (Table 3).  Bmax 
values reflect DAT expression at the cell surface as it has been shown that WIN 
35,428 does not cross the plasma membrane of the intact cell appreciably (Chen 
et al., 2004).  The [3H]-dopamine uptake assays demonstrated that the DUIP of 
cocaine differed significantly between cells transfected with 25% and 100% of 
optimal plasmid levels while WIN 35,428 binding affinity remained unaffected 
(Table 3).  Confocal microscopic analysis further confirmed the changes in COS-
7 cell surface DAT expression observed in the binding experiments (Figure 7). 
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Table 3.  Dopamine uptake inhibition potency of cocaine and binding affinity of WIN 35,428 
at COS-7 cells as a function of amount of WT DAT plasmid introduced.   
Naive COS-7 cells were transiently transfected with 375 (25%), 750 (50%) or 1500 
(100%) ng of WT DAT cDNA plasmid to manipulate the surface expression of DAT.  [3H]-WIN 
35,428 saturation binding assays were performed parallel to [3H]-dopamine uptake inhibition 
assays and under identical conditions.  Mean ± SEM for at least 3 independent experiments. 
 
 
 
 WT DAT Plasmid (% of Optimal) 
 25 50 100 
[3H]-DA uptake 
inhibition 
IC50 (nM) 
Cocaine 228 ± 7 353 ± 20 558 ± 75a
 
[3H]-WIN 35,428 
binding 
   
Kd (nM) 12 ± 2 15 ± 2 14 ± 2 
Bmax (pmol/mg) 0.8 ± 0.4 2.0 ± 0.5 4.0 ± 0.2a
 
aP < 0.05 versus low passage cells for that assay (one-way ANOVA, Newman-Keuls post hoc 
test) 
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Figure 7.  Confocal microscopy of transiently transfected COS-7 cells.   
COS-7 cells were transiently transfected with 25% or 100% of optimal WT DAT cDNA 
plasmid levels.  The expressed DAT protein was visualized with Alexa Fluor 488 (green signal; 
Panels A and B) and cortical F-actin, a marker at the plasma membrane, was visualized with 
rhodamine phalloidin (red signal; Panels C and D).  Shown are representative confocal images of 
three independent experiments.  Cell membrane signal intensities were quantitated for each of 
the four scenarios represented by Panels A – D (Panel E).  Scale bar = 8.00 µm for all the 
images.  The data in Panel E represent an average of three independent experiments.  *P<0.05 
relative to DAT with 100% DNA. 
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Figure 8.  Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding at N2A 
cells expressing varying levels of WT DAT.   
BA 
Cocaine inhibition of [3H]-dopamine uptake (Panel A) and cocaine inhibition of [3H]-WIN 
35, 428 binding (Panel B) under identical conditions at N2A neuroblastoma cells transiently 
transfected with 375 (25%) or 1500 (100%) ng of WT DAT cDNA plasmid.  The data are 
representative of at least 3 independent experiments.  
 
 
All the above experiments studying the DUIP fluctuations of DAT ligands 
were performed in non-neuronal cell systems (CHO and COS-7). DAT is a 
protein expressed in vivo in neuronal cells.  Therefore, to address the 
physiological significance of the cocaine DUIP fluctuation phenomenon, a 
neuronal cell line was tested.  Naive N2A neuroblastoma cells were transiently 
transfected with varying amounts of WT DAT cDNA plasmid.  The amounts of 
plasmid employed in the transfections were 25% and 100% of what is optimal.  
Similar to the COS-7 cell experiment, cocaine DUIP was significantly altered by 
the plasmid titration in N2A cells.  The binding affinities for cocaine and WIN 
35,428 were unaffected (Figure 8 and Table 4).  Again, Bmax values from parallel 
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WIN 35,428 saturation binding analysis indicated that DAT expression was 
predictably shifted by the manipulation of plasmid level (Table 4).   
 
Table 4.  Dopamine uptake inhibition potency and binding affinity of cocaine at N2A 
neuroblastoma cells as a function of amount of WT DAT plasmid introduced.   
Naive N2A cells were transiently transfected with 375 (25%) or 1500 (100%) ng of WT 
DAT plasmid to manipulate the surface expression of DAT.  [3H]-WIN 35,428 binding assays were 
performed parallel to the [3H]-dopamine uptake inhibition assays and under identical conditions.  
Mean ± SEM for at least 3 independent experiments. 
 
 
 WT DAT Plasmid (% of Optimal) 
 25 100 
  
 IC50 (nM) 
[3H]-DA uptake 
inhibition 
 
Cocaine 476 ± 46 789 ± 64a
   
 Ki (nM) 
[3H]-WIN 35,428 
inhibition 
  
Cocaine 229 ± 34 196 ± 11 
   
[3H]-WIN 35,428 binding   
Kd (nM) 25 ± 2 18 ± 3 
Bmax (pmol/mg) 1.3 ± 0.4 2.8 ± 0.5a
 
aP < 0.05 versus low passage cells for that assay (two-tail Student’s t test) 
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B.  Assessing the role of N- and C-terminus of DAT in the DUIP fluctuation 
of cocaine.  
 
Several proteins directly interact with and play an important role in the 
trafficking and functioning of the DAT (reviewed in Torres, 2006).  Differences in 
the DAT brought about by protein interactions might be responsible for the 
formation of two or more distinct conformations of the transporter and cocaine 
may bind to these multiple DAT conformations with different affinities.  To 
investigate the role of protein interactions of DAT in the DUIP fluctuation, N- and 
C-terminal fragments of WT DAT were overexpressed in two cell systems that 
showed the DUIP fluctuation, COS-7 and N2A.  The N- or C-terminal fragments 
of DAT may act as “decoys” by intercepting the DAT modulators and altering the 
dopamine uptake and DUIPs of the DAT blockers.  Studies in COS-7 cells were 
carried out by co-expressing WT DAT and the N- or C-terminal fragments of WT 
DAT.  [3H]-dopamine uptake assays demonstrated that the N- and C-terminal 
fragments of DAT did not exhibit any significant effect on the net dopamine 
uptake at the DAT (Figure 9).  Cocaine inhibition of [3H]-dopamine uptake and 
cocaine inhibition of [3H]-WIN 35,428 binding assays demonstrated that 
overexpression of the N- or C-terminal fragments of the DAT neither affected the 
DUIP nor the binding affinity of cocaine at the DAT in a significant manner 
(Figure 10 and Table 5).  The overexpression of the DAT terminal fragments in 
COS-7 cells was confirmed by confocal microscopy studies (Figure 11).  Studies 
in N2A neuroblastoma cell system were carried out by intentionally manipulating 
the DAT cell surface expression and co-expressing the N- or C-terminal 
fragments of the DAT with the WT DAT.  Cocaine inhibition of [3H]-dopamine 
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uptake assays demonstrated that the N- and C-terminal decoys employed in the 
N2A neuroblastoma cell system do not show any significant change in the DUIP 
of cocaine at the different DAT expression levels (Figure 13 and Table 6).  
 
 
 
Figure 9.  [3H]-Dopamine uptake at DAT in the presence of N- or C-terminal fragments of 
DAT.   
Specific [3H]-dopamine uptake as a percentage of WT DAT was measured in COS-7 cells 
transiently co-transfected with WT DAT and control vector (blue) or N- (green) or C- (yellow) 
terminal fragments of WT DAT.  The N- and C-terminal fragments of DAT are abbreviated as NT 
and CT respectively.  The data represent an average of three independent experiments. 
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Figure 10.  Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding at DAT 
in the presence of N- or C-terminal fragments of DAT.   
Cocaine inhibition of [3H]-dopamine uptake (Panel A) and cocaine inhibition of [3H]-WIN 
35, 428 binding (Panel B) performed in parallel and under identical conditions in COS-7 cells 
transiently co-transfected with 750 ng WT DAT and 750 ng control vector (squares) or N- 
(triangles) or C- (circles) terminal fragments of WT DAT.  The N- and C- terminal fragments of 
DAT are abbreviated as NT and CT respectively.  The data are representative of at least three 
independent experiments.  
 
 
 
Table 5.  Effect of overexpression of N- or C-terminal fragments of DAT on the DUIP and 
binding affinity of cocaine at DAT.   
Cocaine inhibition of [3H]-dopamine uptake and cocaine inhibition of [3H]-WIN 35,428 
binding assays were performed in parallel and under identical conditions in COS-7 cells 
transiently co-transfected with WT DAT and control vector or N- or C-terminal fragments of WT 
DAT.  Mean ± SEM for at least 3 independent experiments. 
 
 
 
 DAT DAT+NT DAT + CT 
Cocaine  
  IC50 (nM)  
[3H]-Dopamine uptake 
inhibition 
474 ± 54 504 ± 40 
 
512 ± 36 
 
  Ki (nM)  
[3H]-WIN 35,428 inhibition 206 ± 29 209 ± 38 256 ± 74 
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Figure 11.  Confocal microscopic localization of DAT N- and C-terminal fragments.   
COS-7 cells were transiently co-transfected with WT DAT and control vector or N- or C-
terminal fragment of DAT.  The expressed N- or C-terminus fragment proteins were visualized 
with the attached GFP tag (green signal) and cortical F-actin, a marker at the plasma membrane, 
was visualized with rhodamine phalloidin (red signal).  The fluorophores were detected separately 
and overlay images were generated.  Scale bar = 8.00 µm for all the images.  Shown are 
representative confocal images of three independent experiments. 
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Figure 12.  Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding at DAT 
in the presence of N- or C-terminal fragments of DAT.   
Cocaine inhibition of [3H]-dopamine uptake in N2A cells transiently co-transfected with 
200 (25%, Panel A) or 1000 (100%, Panel B) ng WT DAT and 500 ng control vector (squares) or 
N- (triangles) or C- (circles) terminus fragments of WT DAT.  All uptake experiments were 
performed under identical conditions.  The data are representative of at least three independent 
experiments. 
 
 
 
Table 6.  Effect of overexpression of N- or C-terminal fragments of DAT on the DUIP and 
binding affinity of cocaine at DAT.   
Cocaine inhibition of [3H]-dopamine uptake in N2A cells transiently co-transfected with 
varying amounts of WT DAT and control vector or N- or C-terminal fragments of WT DAT.  All the 
uptake experiments were performed under identical conditions and on the same day.  Mean ± 
SEM for at least 3 independent experiments. 
  
 
 
 DAT DAT+NT DAT + CT 
  IC50 (nM) 
 
 
25%  DAT DNA 336 ± 34 420 ± 36 
 
326 ± 57 
 
100% DAT DNA 593 ± 124 624 ± 76 682 ± 76 
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Another possibility for the DUIP fluctuation in the present study could be a 
change in the phophorylation state of the DAT. Studies have shown that the DAT 
is N-terminally phosphorylated (Foster et al., 2002, Granas et al., 2003) and 
phosphorylation can affect the cell surface trafficking of the transporter (Holton et 
al., 2005).  To test if the N-terminal phosphorylation plays any role in the DUIP 
shift of cocaine, inhibition of [3H]-dopamine uptake and inhibition of [3H]-WIN 
35,428 binding assays were performed in COS-7 cells expressing human DAT 
(hDAT) and hDAT lacking the first 20 amino acids (del-20 hDAT).  No significant 
difference was observed in the DUIP of cocaine at hDAT compared to the N-
terminal truncated hDAT (Figure 13 and Table 7).  Studying the dopamine uptake 
at del-20 hDAT was another approach to assess the role of N-terminus of the 
DAT in the DUIP fluctuation.  
 
A B
 
 
Figure 13.  Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding at 
hDAT and del-20 hDAT.   
Cocaine inhibition of [3H]-dopamine uptake (Panel A) and [3H]-WIN 35,428 binding (Panel 
B) under identical conditions at hDAT (squares) and del-20 hDAT (circles) transiently transfected 
in COS-7 cells.  The data are representative of 3 independent experiments. 
 
 65
 
  
Table 7.  Effect of N-terminal truncation on the DUIP and binding affinity of cocaine at 
hDAT.   
Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding performed in 
parallel and under identical conditions at hDAT and del-20 hDAT transiently transfected in COS-7 
cells.  Mean ± SEM for at least 3 independent experiments. 
 
 
 
 hDAT del-20 hDAT 
Cocaine 
 IC50 (nM) 
[3H]-Dopamine uptake 
inhibition 
214 ± 56 183 ± 30 
 
 Ki (nM) 
[3H]-WIN 35,428 inhibition 799 ± 139 666 ± 115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 66
V. DISCUSSION 
 
A number of studies have demonstrated that the DUIPs of the classical 
DAT blockers do not correlate well with their apparent binding affinities at the WT 
DAT.  These DAT blockers are more potent in inhibiting [3H]-WIN 35,428 binding 
than in inhibiting [3H]-dopamine uptake (Pristupa et al., 1994; Eshleman et al., 
1999; Wang et al., 2003).  In the present study, the DUIPs of cocaine, mazindol, 
methylphenidate and benztropine followed a decreasing trend with increasing cell 
passage; statistically significant differences in the DUIPs were observed between 
the low and high passages while their binding affinities remained unchanged in 
WT DAT CHO cells.  Neither the DUIP nor the binding affinity of amphetamine 
(DAT substrate) fluctuated at the different passages (Table 1).  The loss of 
correlation between DUIP and binding affinity at DAT might be a unique property 
of DAT blockers that is not exhibited by DAT substrates.  Besides being a 
substrate at the DAT, amphetamine has the ability to induce dopamine efflux via 
the DAT by reversal of the transporter (reviewed in Kahlig and Galli, 2003).  It 
has been shown that amphetamine can cause dopamine efflux in dopamine 
preloaded COS-7 cells (transfected with WT DAT cDNA plasmid), and cocaine 
and other DAT blockers either inhibit or have no effect on the dopamine release 
in these cells (Eshleman et al., 1994; Pifl et al., 1995).  Thus, DAT blockers differ 
from DAT substrates in several respects. 
The ratios of dopamine uptake inhibition potency-to-binding affinity for 
DAT ligands further demonstrate the differences in the behavior of amphetamine 
and the tested DAT blockers at WT DAT CHO cells as a function of cell passage 
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number (Table 2).  The dopamine uptake inhibition Ki value of amphetamine was 
not significantly different from its binding affinity Ki value at WT DAT, evidenced 
by the near unity (1.3 – 1.6) uptake inhibition potency:binding affinity ratios.  On 
the other hand, the dopamine uptake inhibition Ki values of DAT blockers were 
significantly different from their binding affinity Ki values at WT DAT (uptake 
inhibition potency:binding affinity ratios ranged from 2.9 – 8.8 for different DAT 
blockers at the different passages).  Moreover, these ratios were comparably 
different for DAT blockers at low versus high passage WT DAT CHO cells; 
amphetamine did not exhibit such differences.  Thus, two inferences can be 
drawn from the above observations: a) amphetamine is equipotent in inhibiting 
dopamine uptake and WIN binding at WT DAT while DAT blockers are not b) the 
uptake inhibition profile of DAT blockers is comparably different at low and high 
passage WT DAT CHO cells, a phenomenon that does not occur with 
amphetamine.  However, this differential behavior of DAT blockers and DAT 
substrates at DAT in terms of uptake inhibition potencies needs further 
investigation by employing other DAT substrates such as methamphetamine and 
3,4-methylenedioxymethamphetamine (MDMA). 
Contrary to the studies that have shown that DAT expression in the brain 
decreases with aging (Bannon and Whitty, 1997; Salvatore et al., 2003), the 
saturation binding experiments in the present study demonstrated increasing 
DAT surface expression with increasing cell passage (Table 1).  However, the 
binding affinity of [3H]-WIN 35,428 remained unaffected, an observation in 
agreement with the previous reports demonstrating unchanging binding affinities 
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of DAT blockers despite changes in DAT surface expression (Shimizu and 
Prasad, 1991; Hebert et al., 1999).  In another study, altering the cell density (% 
confluence) by over 7-fold to manipulate the total number of DAT molecules in 
each well of the culture dish neither affected the DUIP nor the binding affinity of 
cocaine (Reference: Structural determinants for substrate and inhibitor 
recognition by the dopamine transporter, Dissertation of Okechukwu T. Ukairo, 
Duquesne University).  Cocaine treatment increases DAT surface expression 
(Little et al., 2002; Daws et al., 2002) and amphetamine exposure decreases 
DAT surface expression (Gulley et al., 2002; Saunders et al., 2000; Zahniser and 
Sorkin, 2004).  These inhibitor- or substrate-mediated changes in DAT surface 
expression would be irrelevant here because the present study employed drug 
concentrations that were not high enough and drug incubations that were not 
long enough to cause such changes.  Three µM amphetamine exposure 
increased surface DAT levels within 1 minute, followed by rapid reversion to 
normal levels (Johnson et al., 2005).  This event may or may not be relevant to 
the present experiments, in which amphetamine incubations were performed for 
10 minutes.  Therefore, the potency fluctuation observed with the DAT blockers 
was not a direct consequence of changes in DAT surface expression.  Some sort 
of cell age-related DAT modification might play a significant role in the DUIP 
fluctuations of the DAT blockers.  
Considering the DUIP fluctuation of cocaine with cell passage/state, it is 
unlikely that a single cocaine binding site of the DAT dictates dopamine uptake 
inhibition.  However, no solid evidence exists for two different binding sites for a 
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single DAT ligand on the same DAT protein.  Previous studies provide evidence 
for the existence of DAT in more than one conformation or population.  The DAT 
conformation or population responsible for high affinity binding of DAT blockers 
may be less responsible for dopamine uptake (Wang et al., 2003; Ukairo et al., 
2005).  Distribution of the DAT conformations can be altered by DAT mutation 
(Loland et al., 2002).  Similarly, the distribution of the different DAT 
conformations or populations may be influenced by cell state, possibly by 
alterations in their trafficking to the cell surface.  A plausible explanation for the 
loss of correlation between potency and apparent binding affinity of DAT 
blockers, and DUIP fluctuations with cell passage observed in the present study 
is the existence of two different DAT populations on the cell surface (two-
population model; Wang et al., 2003).  Of the two different populations, 
“Population 1” has a higher affinity for inhibitor binding but is less responsible for 
dopamine uptake.  On the contrary, “Population 2” has a lower affinity for inhibitor 
binding but is largely responsible for dopamine uptake (Figure 14).  The DAT 
blocker has to bind to Population 2 (lower DAT blocker affinity), a population 
underrepresented in binding experiments, to inhibit dopamine uptake.  Binding 
experiments largely represent Population 1 (higher DAT blocker affinity).  Hence, 
the [3H]-dopamine uptake inhibition IC50 values are higher than the inhibition of 
[3H]-WIN 35,428 binding Ki values at the DAT (Table 1).  Extending this 
discussion to the cell passage-related DUIP fluctuation of DAT blockers, the 
surface expression of Population 2 increases with cell passage while surface 
expression of Population 1 remains unaltered; net surface DAT levels are 
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increasing.  In addition to these surface expression changes, the DAT inhibitor 
affinity at Population 2 decreases further with cell age (certain intracellular factors 
may be involved); the net result being a shift in the DUIP of DAT blockers at 
higher passage without any change in their binding affinities.  This model also 
resolves the observation that the binding affinity (Kd) of WIN 35,428 remains 
unaltered despite changes in surface expression in the saturation binding 
experiments (Table 1).  Studies have consistently demonstrated unchanging 
binding affinity with increasing DAT surface expression (Shimizu and Prasad, 
1991; Hebert et al., 1999).  The differences in binding sites of DAT blockers and 
substrates and the fact that amphetamine also acts as a substrate at DAT might 
form the basis for the divergent behavior of DAT blockers and amphetamine with 
respect to potency fluctuation.  Amphetamine-mediated reversal of the 
transporter, a characteristic property not exhibited by the DAT blockers, may 
have an influence on the number of transporter molecules available for dopamine 
uptake or on the DUIP of amphetamine.  The fact that amphetamine (a DAT 
substrate) displaced [3H]-WIN 35,428 (a DAT blocker) in binding assays needs to 
be considered before elucidating the divergent behavior of amphetamine from 
the DAT blockers tested. 
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Figure 14.  Two population model of the DAT.   
Population 1 (blue) displays a higher affinity for WIN 35,428 (green) but is less 
responsible for dopamine uptake.  Population 2 (pink) displays a lower affinity for WIN 35,428 but 
is largely responsible for the dopamine uptake.  WIN 35,428 has to bind to Population 2 to inhibit 
dopamine uptake.  Thus, uptake inhibition experiments principally represent Population 2.  
Binding experiments largely represent Population 1.  Reproduced from Wang et al.,2003. 
 
 
To mimic the cell passage-related changes in surface expression 
observed in WT DAT CHO cells, naive COS-7 cells were transfected with 
different amounts of a cDNA plasmid encoding the WT DAT.  Thus, manipulation 
of DAT surface expression in individual cells was attempted.  Indeed, a 
significant decrease in Bmax was observed when a 4-fold lower amount of DNA 
was employed (Table 3).  Interestingly, the DUIP shift for DAT blockers (similar to 
that observed with different passages of WT DAT CHO cells) correlated with 
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altered DAT surface expression in the COS-7 cells.  Consistent with the previous 
results, the binding affinity remained static.  Quantitative confocal microscopy 
further confirmed the changes in DAT surface expression (Figure 7).  Similar 
experiments were performed in N2A neuroblastoma cells to test the physiological 
relevance of the DUIP shift.  The DUIP fluctuation phenomenon extended to the 
neuronal cell line studied (Table 4). 
As briefly mentioned earlier, intracellular events (e.g., altered 
posttranslational DAT modification pattern or DAT homo- or hetero-
oligomerization) might be controlling the relative distribution of the DAT 
populations (responsible for the DUIP fluctuations of DAT blockers at DAT).  
Physiological changes in the cell cause variations in the glycosylation patterns of 
proteins (Lis and Sharon, 1993; Patel et al., 1994).  N-glycosylation of the DAT 
increased the DUIPs of cocaine-like drugs without affecting their binding affinities 
(Li et al., 2004).  Thus, a slightly different pattern of posttranslational modification 
of DAT can lead to the expression of more than one population of transporters in 
the cell.  DAT homo-oligomerization state affects transporter function and DAT 
ligands can modify this state (Sorkina et al., 2003; Hastrup et al., 2003).  
Several proteins have been implicated in DAT-protein interactions and 
these protein interactions influence the cell surface expression or function of the 
DAT (reviewed in Torres, 2006).  Synuclein and PICK1 interact with the C-
terminal region of the DAT resulting in increased DAT surface expression and 
increased dopamine uptake.  Hic-5 interacts with the amino-proximal portion of 
the intracellular carboxyl terminus of DAT and overexpression of this protein 
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downregulates DAT uptake activity by decreasing the DAT surface expression.  
Syntaxin 1A and RACK1 interact with the N-terminal region of the DAT but the 
effects of these interactions on DAT surface expression and function have not yet 
been established.  Syntaxin 1A interacts with the N-terminal region of the GAT1 
and the NET, and modulates surface expression and transport activity (Deken et 
al., 2000; Horton and Quick, 2001; Sung et al., 2003; Hansra et al., 2004).  
Therefore, it is likely that syntaxin 1A also plays a significant role in regulating the 
activity and/or trafficking of the DAT (GAT1 and NET belong to the same family 
of transporters to which DAT belongs).  Alterations brought about by protein 
interactions with the DAT may be responsible for the formation of different DAT 
populations and cocaine may bind to these dissimilar DAT populations with 
different affinities.  In order to test whether intracellular factor interactions with the 
DAT N- or C-terminus was related to the DUIP fluctuations, GFP fusion 
polypeptides of the DAT N- or C-terminal fragments were coexpressed with WT 
DAT in COS-7 cells.  The DAT fragments were intended to serve as “decoys” by 
intercepting the DAT modulators responsible for the DUIP shifts.  Overexpression 
of the N- or C-terminal decoys did not affect the net dopamine uptake and DUIP 
of cocaine at DAT significantly (Figure 9 and Table 5).  The confocal images 
provided evidence for overexpression of the decoys in the cells (Figure 11).  A 
decoy comprised of the region of the DAT from the beginning of the N-terminus 
to the end of the second transmembrane domain that decreased the DAT uptake 
activity by some unknown mechanism was employed as a positive control (not 
shown) in all the experiments.  Thus, the DAT N- or C-terminal interactions with 
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intracellular proteins do not appear to be responsible for the DUIP shift in COS-7 
cells.  The level of expression of a given DAT-modulating protein may depend on 
the cell type.  To test the possibility of DAT termini-protein interactions, another 
cell system N2A neuroblastoma (that showed the DUIP fluctuation) was 
employed.  This time the DAT surface expression was intentionally manipulated 
(four-fold) to begin with a cell system that already showed the DUIP fluctuation 
before assessing the effect of overexpression of the decoys.  If protein 
interactions at the DAT termini are responsible for the fluctuation, the decoy 
overexpression would shift the DUIP of cocaine at one of the expression levels 
such that it equals the DUIP at the other expression level.  No significant 
differences were observed in the DUIP of cocaine by overexpression of the 
decoys.  Thus, DAT N- or C-terminal interactions with intracellular proteins do not 
appear to account for the DUIP shift in N2A cells.  Another approach for future 
studies would be to overexpress a given DAT interacting factor in a DAT-bearing 
cell system to test for DUIP shifts. 
Another possibility for the DUIP fluctuation in the present study could be a 
change in the phosphorylation state of the DAT.  The N-terminal region of the 
DAT possesses multiple sites for phosphorylation (Foster et al., 2002; Granas et. 
al 2003; Lin et al., 2003).  Deletion of the first 22 N-terminal residues, which 
included the terminal five serines, abolished detectable hDAT phosphorylation 
(Granas et al., 2003).  Additionally, dopamine uptake in mouse striatum was 
significantly affected by a wide-spectrum inhibitor of protein kinases (Simon et 
al., 1997).  A change in the phosphorylation state of the DAT may result in the 
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existence of cell surface DAT in two or more conformations or populations with 
different phosphorylation states which may affect the ability of cocaine to bind to 
the transporter.  The hDAT mutant, del-20 hDAT, employed in the present study 
lacks the first 20 amino acids including the five N-terminal serines that have been 
demonstrated to be the most important residues in DAT phosphorylation.  
Removal of these serines did not affect the DUIP of cocaine (Table 7).  Thus, the 
N-terminal phosphorylation of DAT, specifically involving the first five serines, is 
not associated with the DUIP shift.  However, other serine and threonine 
residues are present in the DAT sequence; the role of phosphorylation in creating 
distinct DAT populations cannot be totally ruled out.  Phosphorylation can occur 
at any of the serine or threonine residues in the DAT that are exposed to the 
intracellular compartment.  To completely assess the role of phosphorylation 
state of DAT in DUIP fluctuations, DAT mutants with N-terminal truncations 
lacking the other N-terminal serines and threonines, C-terminal truncations and 
point mutants at the serines and threonines in the intracellular loops should be 
employed. 
Further studies investigating the occurrence and regulation of the different 
DAT populations or conformations and their association with the DUIP shifts may 
help identify the factors influencing the DAT activity, which in turn may identify 
targets for anti-cocaine and anti-amphetamine therapeutics. 
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